Weiss, Robert
Regeneron (United States)
7 papers on CoChatORCID 0000-0003-4451-8373
Most cited papers
- Verified
Original Papers. Success and Predictors of Blood Pressure Control in Diverse North American Settings: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Cushman, W. C., Ford, C. E., Cutler, J. A., Margolis, K. L., Davis, B. R., Grimm, R. H., Black, H. R., Hamilton, B. P., Holland, J., Nwachuku, C., et al. (2002) · The Journal of Clinical Hypertension
Blood Pressure and Hypertension StudiesSodium Intake and Health
Cited by 979
- Verified
Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia: The LAPLACE-2 Randomized Clinical Trial
Robinson, J. G., Nedergaard, B. S., Rogers, W. J., Fialkow, J., Neutel, J. M., Ramstad, D., Somaratne, R., Legg, J. C., Nelson, P., Scott, R., et al. (2014) · JAMA
Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism
Cited by 496
- Verified
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., et al. (2019) · The Lancet Diabetes & Endocrinology
Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 315
- Verified
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)
Ballantyne, C. M., Weiss, R., Moccetti, T., Vogt, A., Eber, B., Sosef, F., & Duffield, E. (2007) · The American Journal of Cardiology
Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism
Cited by 196
- Verified
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials
Stein, E. A., Giugliano, R. P., Koren, M. J., Raal, F. J., Roth, E. M., Weiss, R., Sullivan, D., Wasserman, S. M., Somaratne, R., Kim, J. B., et al. (2014) · European Heart Journal
Lipoproteins and Cardiovascular HealthLipid metabolism and disorders
Cited by 130
- Verified
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
Hagström, E., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Danchin, N., Diaz, R., Goodman, S. G., Harrington, R. A., Jukema, J. W., et al. (2022) · Circulation
Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research
Cited by 118
- Verified
Efficacy and safety of canagliflozin used in conjunction with sulfonylurea in patients with type 2 diabetes mellitus: a randomized, controlled trial
Fulcher, G., Matthews, D. R., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Weiss, R., Rosenstock, J., Capuano, G., Desai, M., Shaw, W., et al. (2015) · Diabetes Therapy
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 44
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free